PT  - JOURNAL ARTICLE
AU  - Carien L. Creutzberg
TI  - Adjuvant Chemotherapy for Endometrial Cancer: Unproven
AID  - 10.1111/IGC.0b013e3181f35473
DP  - 2010 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - 1105-1108--1105-1108
VI  - 20
IP  - 7
4099  - http://ijgc.bmj.com/content/20/7/1105-1108.short
4100  - http://ijgc.bmj.com/content/20/7/1105-1108.full
SO  - Int J Gynecol Cancer2010 Oct 01; 20
AB  - High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with significant comorbid diseases. Because patients with high-risk EC are at increased risk of distant metastases and EC death, the use of adjuvant chemotherapy has been investigated in several trials. Trials comparing radiotherapy and chemotherapy have not shown survival difference. A first trial comparing combinations of chemotherapy and radiotherapy with radiotherapy alone suggested progression-free survival benefit. Toxicity and quality of life data are lacking. The role of adjuvant chemotherapy for endometrial carcinoma remains unproven. High-risk EC remains the challenge for further research.